arrow
A

Athina Christopoulou

s. andrew hospital
H指数:17
被引数:1,391

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.

插入式阿维鲁唑胺联合铂类为基础的化疗在广泛期小细胞肺癌患者中的应用(PAVE):一项多中心Hellenic Cooperative Oncology Group II期研究的最终结果、免疫表型分析和生物标志物分析。

2025-07-250
OAAI
Li-Fraumeni: Genetic testing of Breast/ovarian cancer patients unmask familial pathogenic germline variants in TP53 gene. Clinical implications and family counselling

Li-Fraumeni综合征:对乳腺癌/卵巢癌患者进行遗传检测可揭示TP53基因中的家族性致病性生殖细胞系变异。临床意义与家族咨询

BREAST
IF7.9
2025-02-010
OAAI
Integrative analysis of circulating tumor cells (CTCs) and exosomes from small-cell lung cancer (SCLC) patients: a comprehensive approach
2024-11-220
OAAI
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
2024-10-211
OAAI
Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation

多基因风险评分 (PRS) 与NGS小组测试相结合,可提高遗传性乳腺癌风险评估的准确性

2024-08-210
OAAI
Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group
2024-03-010
PRE
Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
2023-10-010
OA
Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis

晚期非小细胞肺癌患者数字支持的临床和分子研究: snf-climedin,一项前瞻性随机希腊肿瘤协作组 (HeCOG) 研究: 中期分析

2023-10-011
OAAI
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Patras免疫治疗评分模型对nivolumab或pembrolizumab治疗晚期NSCLC患者的预测和预后的验证: 来自欧洲多中心研究的结果

2022-09-081
OAAI
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

晚期非小细胞肺癌患者晚期肺癌炎症指数 (ALI) 与免疫检查点抑制剂疗效的相关性研究

2021-10-0158
OAAI
Phased avelumab combined with chemotherapy as first-line treatment in extensive stage small cell lung cancer (PAVE): A phase II Hellenic Cooperative Oncology Group study

分期avelumab联合化疗作为广泛期小细胞肺癌 (PAVE) 的一线治疗: 一项II期希腊合作肿瘤小组研究

2021-09-011
OAAI
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

一项观察性研究,评估在希腊实际临床环境中使用阿法替尼治疗的晚期EGFR突变阳性非小细胞肺癌患者表皮生长因子受体 (EGFR) 突变的分子流行病学和直接医疗费用

2021-08-012
OAAI
Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study
2021-07-010
OAAI
Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller
2021-03-0118
PREAI
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
2020-09-2524
PREAI
Prevention and prophylaxis (thromboprophylaxis - ACT) of cancer associated thrombosis (CAT) in high risk oncology patients: ACT4CAT
2020-09-010
OAAI